Jon Shanter, Director, Vaccine Process Development, Merck
“Regulatory opinions for mRNA will take time to stabilize but I’d expect the scope of this network to play an important role in accelerating that, which will mean getting better drugs to patients faster”
Theresa Goletz, Global Head Of Analytical Immunology & Cellular Platform, GSK
“This network offers us the valuable chance to discuss the things that don't appear in scientific publications as well as the chance to regularly engage with a trusted group of peers and see how the areas you’re interested in are evolving and advancing outside your company”
Ryan Shaler, Associate Director, Immunology & mRNA Discovery, Sonata Therapeutics
"It is so useful to have a sounding board of people doing the same work and facing the same challenges as us. Having a network like this will allow us to get answers faster than trying to muddle our way through it ourselves."
Ready to join the mRNA-Based Therapeutics: Searchlight network?